semaglutide nejm weight loss In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintide–semaglutide resulted in a significantly lower body than placebo at 68 weeks. Full trial results Weight Regain after Stopping Obesity
Description
Early intervention prevents minor problems from becoming major complications requiring extensive treatment
But as more real-world data and research emerge, a much clearer picture is forming
doi: 10.1038/ncb1101-1014
Will people travel more because they are more active and spending less of their income and time eating at restaurants
